SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-24-008130
Filing Date
2024-05-14
Accepted
2024-05-14 16:05:29
Documents
52
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q acxp-20240331x10q.htm   iXBRL 10-Q 1118518
2 EX-31.1 acxp-20240331xex31d1.htm EX-31.1 12636
3 EX-31.2 acxp-20240331xex31d2.htm EX-31.2 12641
4 EX-32.1 acxp-20240331xex32d1.htm EX-32.1 5509
5 EX-32.2 acxp-20240331xex32d2.htm EX-32.2 5547
  Complete submission text file 0001558370-24-008130.txt   4095907

Data Files

Seq Description Document Type Size
6 EX-101.SCH acxp-20240331.xsd EX-101.SCH 30212
7 EX-101.CAL acxp-20240331_cal.xml EX-101.CAL 17627
8 EX-101.DEF acxp-20240331_def.xml EX-101.DEF 112290
9 EX-101.LAB acxp-20240331_lab.xml EX-101.LAB 273717
10 EX-101.PRE acxp-20240331_pre.xml EX-101.PRE 210731
56 EXTRACTED XBRL INSTANCE DOCUMENT acxp-20240331x10q_htm.xml XML 435805
Mailing Address 259 LIBERTY AVENUE STATEN ISLAND NY 10305
Business Address 259 LIBERTY AVENUE STATEN ISLAND NY 10305 917-533-1469
Acurx Pharmaceuticals, Inc. (Filer) CIK: 0001736243 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40536 | Film No.: 24944219
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)